What the semaglutide research paper evidence tells you — and what it doesn't

You're looking at the STEP 1 numbers and wondering if they mean anything for you

The scenario is familiar: someone shares a chart from a clinical paper, or a GP mentions a study, and you're left trying to work out whether 15% weight loss is achievable or a best-case outlier. STEP 1 is the most-cited semaglutide paper for weight management. It recruited adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, who did not have type 2 diabetes. Over 68 weeks, participants on semaglutide 2.4mg lost an average of around 15% of body weight; those on placebo lost around 2.4%. The results were published in the New England Journal of Medicine (STEP 1, 2021) and form the evidentiary backbone of the UK licence for Wegovy.

That 15% average is exactly that, an average across a large, diverse group. Some participants lost more, others less. Age, starting weight, metabolic health, adherence to the lifestyle programme that ran alongside the medicine, and genetic factors all influenced individual outcomes. So the paper tells you what is plausible and what the medicine does at a population level. It does not tell you what will happen specifically in your case. That is a clinical judgement, which is why semaglutide remains a prescription-only medicine in the UK.

One practical note: trial participants were asked to keep pens refrigerated. If you go on to start treatment, that means a permanent space in the fridge door rather than the gym bag, something worth factoring into your routine from day one.

Beyond STEP 1: what the wider semaglutide research picture covers

STEP 1 is not the only paper. The broader STEP programme examined semaglutide in adults with type 2 diabetes (STEP 2), in people following an initial weight-loss period (STEP 3), and in the context of long-term cardiovascular outcomes (the SELECT trial, published in 2023). SELECT enrolled over 17,000 adults with established cardiovascular disease and obesity but without diabetes; semaglutide 2.4mg reduced the risk of major cardiovascular events (heart attack, stroke or cardiovascular death) by around 20% compared with placebo. That cardiovascular finding is now reflected in Wegovy's UK licence, which extends beyond weight management alone.

More recently, the MHRA approved a 7.2mg dose of Wegovy in 2026. A dedicated single-dose 7.2mg pen was confirmed on 14 April 2026 for adults with a BMI of 30 or above, with trial data reporting roughly 20.7% average weight loss over 72 weeks. You can read our overview of the higher-dose evidence for more detail on how that compares to earlier trial data.

The NHS medicines page for semaglutide summarises the approved uses and licensed dose schedules in plain language, and is worth reading alongside the primary papers if you want both the clinical evidence and the patient-facing summary in one place.

What the research does not settle, and why that matters for a consultation

Clinical papers answer group-level questions with carefully controlled conditions. They are less good at answering individual ones. A few things the existing semaglutide literature does not resolve for any given person: how quickly nausea settles during the titration period (highly variable), whether the cardiovascular benefit applies to someone without established heart disease, and how sustainable the weight loss is if the medicine is continued beyond the trial period under real-world prescribing. STEP 4 is instructive here, it showed that discontinuing semaglutide after achieving weight loss led to significant regain, suggesting the medicine works while it is being taken rather than resetting biology permanently. The semaglutide treatment overview covers this long-term context in more detail.

There are also populations the trials did not primarily focus on. People with a history of pancreatitis, medullary thyroid carcinoma or certain other conditions were excluded from the STEP programme, which is one reason those histories are raised during a clinical consultation before any prescription is issued. The papers set the boundary of what we know; the prescriber applies that knowledge to your specific circumstances. Side effects during the titration period are also worth understanding in advance, and if you are curious about digestive symptoms in particular, our page on what causes belching on Wegovy and how common it is gives a useful breakdown.

If cost is part of your decision, our Wegovy pricing page sets out what private treatment involves, there are no subscriptions at nume, and every repeat order goes through a fresh clinical review. For a full picture of the treatment options currently available, the weight-loss treatments page is the right starting point.

How trial eligibility criteria compare to the UK private prescription route

STEP 1's eligibility criteria map closely onto the UK licensed indication: adults with a BMI of 30 or above, or 27 or above with a qualifying weight-related condition. That is also the threshold for a private prescription through a regulated UK pharmacy. NICE's recommendation for semaglutide (TA875) applies stricter criteria for NHS access (requiring use within a specialist weight management service for a maximum of two years) but the private licensed route follows the SmPC criteria, not the NICE commissioning guidance. Our guide to the semaglutide 1mg dose explains where that starting-point dose fits within the overall titration schedule.

Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance, typically 2.5 kg/m² below the standard figures. A prescriber at a clinician-led service will factor that in as part of the assessment.

BMI alone is a starting point, not the whole picture. Prescribers weigh up your medical history, current medications, relevant test results and the overall risk-benefit balance before confirming suitability. The research gives them a framework; the consultation applies it to you. If you'd like to understand your options, checking your eligibility is a sensible first step.